377 results on '"Kreuz W"'
Search Results
2. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review
3. Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors
4. Development of a Quasispecies of Human Immunodeficiency Virus Type 1 in vivo
5. Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies
6. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema
7. Observational Immune Tolerance Induction Research Program (ObsITI)—a multifaceted approach to explore immune tolerance induction: FEN21
8. A review of immune tolerance induction with Haemate® P in haemophilia A
9. Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema
10. A common 253‐kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3
11. Risk of angioedema following invasive or surgical procedures in HAE type I and II – the natural history
12. Progress report on the experience of immune tolerance induction with a VWF/FVIII concentrate in haemophilia a patients in Colombia: PO 152
13. Immune tolerance induction (ITI) according to the Bonn protocol in haemophilia A patients with inhibitors using a plasma-derived VWF-containing factor VIII concentrate: two paediatric case reports: PO 143
14. Immuno-monitoring of patients with severe hemophilia A: PB 1.38–6
15. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?
16. Minor head injury as cause and co-factor in the aetiology of stroke in childhood: a report of eight cases. (Paper)
17. On-demand therapy after ITT failure in patient with von Willebrand disease type 3 and alloantibodies: PO-MO-242
18. Results of Ankle Prosthesis in Patients with Severe Hemophilic Arthropathy: Follow Up: PO-WE-180
19. ITI with a VWF/ FVIII concentrate in hemophilia A patients with inhibitors and a poor prognosis for ITI success: Progress report on octanate® in the ObsITI Study: PO-WE-045
20. Post-trauma coagulation and fibrinolysis in children suffering from severe cerebro-cranial trauma
21. Treatment of consumption coagulopathy with antithrombin concentrate in children with acquired antithrombin deficiency – A feasibility pilot study
22. Prothrombotic risk factors in childhood stroke and venous thrombosis
23. Prevalence and outcome of intracranial haemorrhage in haemophiliacs – a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH)
24. Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood
25. Prevention of joint damage in hemophilic children with early prophylaxis
26. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A
27. Risk of Angioedema following operative and invasive Procedures in Hereditary Angioedema due to C1-inhibitor Deficiency: 1032
28. Pharmacokinetic Berinert P Study Of Subcutaneous Versus Intravenous Administration In Subjects With Moderate Hereditary Angioedema - The Passion Study: 389
29. Idiopathic Angioedema and Coagulation Factor XII Mutation: 372
30. A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation
31. Session W1.4 Inhibitor incidence in previously untreated patients (PUPs) with haemophilia A and B - final evaluation of the prospective PUP study conducted by the paediatric committee of the GTH (German, Swiss, and Austrian Society of Thrombosis and Haemostasis Research): 17FP07
32. Immune tolerance induction with Octanate® in haemophilia A patients with inhibitors and a poor prognosis: progress report on an ongoing prospective data collection: 08P43
33. Management of acute hereditary angioedema attacks during pregnancy, delivery and breast-feeding and their treatment with C1 inhibitor concentrate: 25
34. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series
35. Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis
36. Inhibitors in haemophilia A: the role of VWF/FVIII concentrates – a meeting report
37. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene
38. Haemate® P/Humate-P® for the treatment of von Willebrand disease: considerations for use and clinical experience
39. von Willebrandʼs disease: from discovery to therapy – milestones in the last 25 years
40. Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor
41. Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism
42. HEREDITARY ANGIOEDEMA IN CHILDREN AND ADOLESCENTS: O6-12
43. Retrochorionic Hematoma in Congenital Afibrinogenemia: Resolution with Fibrinogen Concentrate Infusions
44. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO®) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria
45. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development
46. Factor FVII deficiency: clinical manifestation and molecular genetics of more than 650 subjects with FVII gene mutations: 17 FP 486
47. A patient with hemophilia A and achondroplasia - a case report: 16 PO 466
48. Response to anti CD20 monoclonal antibody Rituximab and Epitope mapping of inhibitory antibodies in patients with acquired haemophilia: 01 PO 12
49. Combined therapy in human immunodeficiency virus-infected children —a 4-year experience
50. Treatment of diarrhoea in human immunodeficiency virus-infected patients with immunoglobulins from bovine colostrum
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.